新型冠状病毒肺炎导致的急性呼吸窘迫综合征治疗:与传统急性呼吸窘迫综合征的不同  

Therapy of coronavirus disease 2019 induced acute respiratory distress syndrome is different from traditional acute respiratory distress syndrome

作　　者：潘纯[1] 谢剑锋[1] 邱海波[1] 杨毅[1] Pan Chun;Xie Jianfeng;Qiu Haibo;Yang Yi(Department of Critical Care Medicine,Zhongda Hospital,School of Medicine,Southeast University,Nanjing 210009,China)

机构地区：[1]东南大学附属中大医院重症医学科,南京210009

出　　处：《中华烧伤杂志》2020年第5期330-333,共4页Chinese Journal of Burns

基　　金：新型冠状病毒感染的肺炎疫情应急项目(2020YFC0843700);重大新药创制科技重大专项(2020ZX09201015);江苏省社会发展专项(BE2019749、BE2018743);江苏省医学重点学科(实验室)(ZDXKA2016025);江苏省六大人才高峰项目(TD-SWYY-003);江苏省医学重点人才项目(ZDRCA2016082)。

摘　　要：新型冠状病毒肺炎(COVID-19)已成为全球公共卫生事件,对全球人民生命安全构成极大的威胁。而COVID-19导致的急性呼吸窘迫综合征(ARDS)与其他疾病导致的ARDS在病理生理基础、临床表现等方面有相同的地方,但也有很大的区别,从而导致临床治疗的差异。因此,了解COVID-19导致的ARDS与其他病因导致ARDS的异同,是目前临床医师对COVID-19导致的ARDS进行临床决策的基础。Coronavirus disease 2019(COVID-19)has become a global public health emergency threatening people′s lives around the world.Although the acute respiratory distress syndrome(ARDS)induced by COVID-19 is similar to the ARDS caused by other diseases in terms of pathophysiological basis and clinical manifestations,they are also different in many aspects,which lead to different clinical therapies.Therefore,understanding the differences and similarities of ARDS induced by COVID-19 and other diseases currently are the basis for clinicians to make decisions for the treatment of COVID-19 induced ARDS.

关 键 词：机械通气 急性呼吸窘迫综合征 新型冠状病毒肺炎 原发病 免疫调理 

分 类 号：R644[医药卫生—外科学] R61[医药卫生—临床医学] R541.7+5